Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.
PRNewswire - October 13, 1999
Henry F. Blissenbach, Pharm.D., president and chief operating officer of Chronimed, said, "The Clinical Partners acquisition was made to expand Chronimed's level of clinical expertise in HIV disease management. Visible Genetics' decision to select Chronimed to participate in this study clearly shows that we are well on our way to achieving those goals. In addition, our willingness to be involved with this study shows our desire to provide the best and most current treatment options for the patients we manage."
According to Dean Winslow, M.D., VGI's vice-president of Regulatory and Clinical Affairs, "Studies have shown that over time the HIV virus will develop resistance to a given drug treatment strategy. As a result, it is important to change the patient's drug treatment regimen as the virus changes. We are pleased to be at a point where we can show that understanding how and when the virus mutates will lead to improved quality of life for people with HIV." Dr. Winslow went on to say, "We are equally pleased to have Clinical Partners involved with our trial. Their long history in dealing with HIV disease management, and their expansive database of patients and physicians, made them the perfect partner as we validate our test."
Chronimed Inc. is a healthcare company specializing in services, products, and case management for patients with chronic health conditions. Such conditions include diabetes, HIV/AIDS, organ transplantation, and complex diseases treated with self-injectable drugs. The Company develops, manufactures, markets, and distributes pharmaceuticals, medical diagnostic products, and patient education materials nationwide directly to individuals, patients of managed care organizations, and to institutions that serves these patients.
Visible Genetics Inc. manufactures and markets high-performance automated DNA sequencing systems and complete kits for the analysis of genes linked to disease. The Company's OpenGene(TM) system employs proprietary stratified DNA testing and single-tube, single-step sequencing methods to significantly reduce the time and cost involved in identifying clinically relevant genetic information. VGI is a leader in the emerging field of pharmacogenomics, which will use genetic information in the identification and analysis of genes to improve patient care and reduce healthcare costs. For more information on VGI visit http://www.visgen.com
As a cautionary note to investors, certain matters discussed in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; the Company's ability to execute its service and product sales plans; changes in the status of managed care contracts; and the risks described from time to time in the Company's SEC reports.
SOURCE Chronimed Inc.
CONTACT: Paul S. Dunn, Investor Relations, or Maurice R. Taylor, II, Chairman and CEO, 612-979-3600, both of Chronimed Inc. /
Web Site: /http://www.visgen.com /
991013
PR991028
Copyright © 1999 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .